Cellectis Advances UCART123 Study in AML Treatment, Updates on Ongoing Clinical Trial

Cellectis S.A. has announced an update on its ongoing clinical study of UCART123 in relapsed or refractory acute myeloid leukemia (AML) treatment. The study aims to determine the Maximum Tolerated Dose and Recommended Phase 2 Dose of UCART123v1.2, an allogeneic engineered T-cell therapy targeting CD123. The study is currently in Phase I and follows an interventional design with a single-group assignment. The update could positively influence Cellectis S.A.'s stock performance, but the competitive landscape in the biotech industry remains intense.

Title: Cellectis S.A. Announces Progress in UCART123 Clinical Study for AML

Cellectis S.A. has recently provided an update on its ongoing Phase I clinical study of UCART123 in the treatment of relapsed or refractory acute myeloid leukemia (AML). The study, which aims to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of UCART123v1.2, an allogeneic engineered T-cell therapy targeting CD123, has seen significant progress.

The study, conducted under an interventional design with a single-group assignment, is currently in Phase I. The update indicates that the company is moving forward with its clinical trials, which could potentially have a positive impact on Cellectis S.A.'s stock performance.

The competitive landscape in the biotech industry remains intense, with numerous companies vying for market share in innovative cancer treatments. Cellectis S.A.'s progress with UCART123v1.2 could position the company favorably in this competitive environment.

References:
[1] https://www.stocktitan.net/news/SNTI/senti-bio-determines-recommended-phase-2-dose-rp2d-in-phase-1-study-iqr83mjqcpe8.html